Imprimis Pharmaceuticals announced Thursday it plans to introduce a less expensive alternative to cyclosporine (Restasis—Allergan). According to Imprimis CEO Mark Baum, the therapy will cost $0.99 for a 1-month supply, with refills starting at $79 a month. Allergan recently sparked controversy after making a deal with the Saint Regis Mohawk tribe that would protect certain patents on Restasis. Earlier this week, however, a U.S. judge invalidated the patents. Imprimis, which makes compounded medications for expensive prescription drugs, said it will offer a customizable topical formulation of cyclosporine. Baum noted that cyclosporine itself is "off-patent, (it) happens to be inexpensive, and we buy it from FDA-registered manufacturers." The company will begin selling prescriptions on November 1, he said.